ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology's Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accept ...

Haemonetics (HAE) has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics' Plasma business continues to grow, banking on an expanding end-user market for plasma-derived biopharmaceuticals. In the second quarter of 2024, U.S. collection volume growth was robust. Both North America software and Europe disposable revenues witnessed double-digit ...

NTLA-2002 Development and Clinical Trial - NTLA-2002 is a single-dose CRISPR-based gene editing therapy designed to treat hereditary angioedema (HAE) by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein [1][4] - The HAELO Phase 3 trial is a global, randomized, double-blind, placebo-controlled study involving 60 adults with Type I or Type II HAE, with patients randomized 2:1 to receive a single 50 mg infusion of NTLA-2002 or placebo [2] - The primary endpoint of the Phase 3 trial is the change in the number of HAE attacks from week 5 through week 28 [2] - Interim Phase 1 clinical data showed dramatic reductions in attack rates and consistent, deep, and durable reductions in kallikrein levels [3] Regulatory Designations and Potential Impact - NTLA-2002 has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. FDA, Innovation Passport by the U.K. MHRA, PRIME Designation by the European Medicines Agency, and Orphan Drug Designation by the European Commission [4] - NTLA-2002 has the potential to become the first one-time treatment for HAE, addressing the real-world needs of patients, physicians, and payors [1][4] Hereditary Angioedema (HAE) Overview - HAE is a rare, genetic disease affecting approximately one in 50,000 people, characterized by severe, recurring, and unpredictable inflammatory attacks that can be life-threatening [5] - Current treatment options for HAE include lifelong therapies requiring chronic intravenous or subcutaneous administration, often with breakthrough attacks despite treatment [5] Intellia Therapeutics Overview - Intellia Therapeutics is a leading clinical-stage gene editing company focused on CRISPR-based therapies, with in vivo programs targeting disease-causing genes directly inside the human body and ex vivo programs for cancer and autoimmune diseases [6][7] - The company is advancing its modular gene editing platform, with NTLA-2002 being its second in vivo candidate to enter late-stage clinical development [1]

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows: Title: Long-Term ...

Haemonetics Corporation (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company's Hemostasis Management franchise is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism. Meanwhile, headwinds from adverse foreign exchange effects pose concern to Haemonetics' operations. In the past year, this Zacks Rank #2 (Buy) company has lost 14.5% against the industry's 24.6% growth an ...

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be pr ...

Core Insights - Deucrictibant shows a 93% reduction in HAE attack rates and maintains efficacy over long-term use, positioning it as a potential preferred therapy for HAE management [1][2][4] - The median onset of symptom relief for on-demand treatment is approximately 1.1 hours, with a high percentage of attacks resolving within 24 hours [1][5] - The safety and tolerability profile of deucrictibant has been confirmed through multiple studies, indicating no new safety signals [6][4] Prophylactic Program - The CHAPTER-1 study demonstrated that 90% of participants receiving deucrictibant reported well-controlled HAE at week 12 compared to 37.5% in the placebo group [3] - Participants treated with deucrictibant reported higher satisfaction regarding effectiveness and global satisfaction compared to those on placebo [3] On-Demand Program - In the RAPIDe-2 study, the median time to onset of symptom relief was 1.1 hours, with 98.5% of attacks achieving relief within 12 hours [5] - The median time to complete attack resolution was 11.5 hours, with 85.8% of attacks resolving completely within 24 hours [5] - A propensity-score matched analysis indicated that outcomes for attacks treated with deucrictibant were more favorable than those treated with standard care [5] Safety - Cardiovascular safety assessments of deucrictibant showed no adverse effects on cardiovascular parameters in both nonclinical and clinical studies [6] About Deucrictibant - Deucrictibant is a novel oral bradykinin B2 receptor antagonist designed to prevent and treat HAE attacks, with both extended-release and immediate-release formulations under development [8] About Pharvaris - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for HAE, with ongoing Phase 3 studies planned for both prophylactic and on-demand treatment [9]

Haemonetics (HAE) has been on a downward spiral lately with significant selling pressure. After declining 15.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock ...

Haemonetics Corporation (HAE) recently announced the full market release of its VASCADE MVP XL — a mid-bore venous closure system. The VASCADE MVP XL system will now be available to U.S. hospitals as the newest addition to the company's VASCADE portfolio of vascular closure systems. With the full market release underway and an ongoing clinical trial program, the company is well-positioned to broaden the indications for the VASCADE MVP XL system to even larger access points. The latest development is expecte ...